Exfoliant Allergy or Irritation? AHAs, BHAs, and Enzymes Explained Clearly

Irritant contact dermatitis (ICD) from exfoliants is dose-dependent and non-immune — it causes stinging and redness within minutes of application, can affect anyone regardless of prior exposure, and resolves when the product is removed and barrier repair begins. True allergic contact dermatitis (ACD) is a Type IV T-cell-mediated immune reaction requiring prior sensitization; it causes an itchy papulovesicular (bumpy, blister-like) rash appearing 24–72 hours after contact. About 80% of all contact dermatitis is irritant. For exfoliants specifically, AHAs and BHAs almost exclusively cause ICD; enzyme exfoliants (papain, bromelain) are the rare exception where true ACD develops.

True Type IV allergic contact dermatitis to glycolic acid or salicylic acid is very rare in clinical practice. What patients experience as a 'glycolic acid allergy' is almost universally irritant contact dermatitis — concentration-dependent acid burning that occurs in anyone when threshold concentrations are exceeded. AHAs work at pH 3.5–4.0, which is inherently low enough to irritate compromised skin. If you develop a delayed (24–72 hour), itchy, papulovesicular rash from a specifically low-concentration product, request comprehensive patch testing with a cosmetic supplemental series from a board-certified dermatologist to confirm whether true ACD is present.

Enzyme exfoliants and acid exfoliants carry different risk profiles, and neither is universally safer. Acid exfoliants (AHAs, BHAs, PHAs) are primarily irritants — they do not cause true allergic contact dermatitis under normal use conditions. Enzyme exfoliants (papain, bromelain) are gentler irritants in most people but carry a real risk of true Type IV allergic sensitization and, in rare cases, immediate IgE-mediated contact urticaria. For patients who have over-exfoliation ICD, enzyme formulas at low concentrations may be less acutely irritating than high-percentage glycolic acid. For patients with food sensitivity to papaya or pineapple, enzyme exfoliants are higher risk. PHAs (gluconolactone, lactobionic acid) are the gentlest of all chemical exfoliant categories across most skin types.

Yes — papain (from papaya) and bromelain (from pineapple) are documented Type IV allergens. Repeated topical exposure can sensitize the immune system, with subsequent exposures triggering a delayed itchy papulovesicular dermatitis 24–72 hours after contact. More rarely, these enzyme proteins can cross-link IgE antibodies on mast cells and trigger immediate contact urticaria (hives within minutes) in patients with concurrent IgE sensitization to papaya or pineapple food allergens. If you develop hives or facial swelling after applying an enzyme exfoliant, discontinue use immediately and consult an allergist. If you have a known papaya or pineapple food allergy, patch test or avoid enzyme exfoliants entirely.

Yes — PHAs (polyhydroxy acids, principally gluconolactone and lactobionic acid) have a gentler irritation profile than AHAs and BHAs for several reasons. Their larger molecular size slows skin penetration and reduces acute acid irritation. Unlike AHAs, PHAs have humectant properties that partially compensate for the barrier disruption that accompanies exfoliation. Clinical studies in patients with rosacea and atopic dermatitis have found PHAs to be better tolerated than equivalent AHA concentrations. PHAs are still photosensitizers like all chemical exfoliants, so daily SPF remains mandatory. For patients with a history of exfoliant ICD, PHAs are the recommended reintroduction category before attempting AHA or BHA products.

Sensitive skin should be exfoliated no more than once or twice per week at low concentration (5–10% AHA, 1–2% BHA, or 8–10% PHA). Starting once per week and building tolerance over 4–6 weeks is advisable. Exfoliating daily — even with gentle PHAs — accumulates barrier disruption and eventually produces symptoms indistinguishable from irritant dermatitis. The temptation to exfoliate more frequently when skin looks dull should be resisted; true skin cell turnover takes approximately 28–40 days and is not accelerated by more frequent exfoliation. Pairing each exfoliant application with a bland fragrance-free moisturizer applied immediately afterward reduces irritation risk.

Peeling and burning are the two most common signs of irritant contact dermatitis from over-exfoliation. Burning occurs because acids below pH 4 irritate free nerve endings in the epidermis — this is the same mechanism as the sting from applying vitamin C serum (ascorbic acid) to broken skin. Peeling is accelerated desquamation: the exfoliant has disrupted the corneocyte cohesion that normally governs controlled skin shedding. Both indicate that barrier function is compromised. The first management step is stopping all exfoliants immediately and applying a plain emollient (ceramide cream or petrolatum) twice daily for 4 weeks to rebuild the barrier before reconsidering any exfoliant use. If burning or peeling occurs with a very low concentration product on first use, consult a dermatologist to rule out a rare Type IV reaction.

For enzyme-containing exfoliants (papain, bromelain), a 48–72 hour inner forearm patch test before full facial application is strongly recommended, especially if you have any food sensitivity to papaya or pineapple. Apply a small amount, cover with a bandage, and check at 24 and 48 hours for erythema, papules, or vesicles. For acid-class exfoliants (AHA, BHA, PHA), a forearm test can reveal whether acute acid irritation occurs at the specific product's concentration, but it will not predict delayed ACD given the rarity of true acid sensitization. A practical low-effort first step for any new exfoliant is a single behind-the-ear application and observation for 24 hours before full use.

At-home chemical peels are safe within regulated OTC concentrations when used as directed — typically 5–15% AHA or 1–2% BHA, applied 1–3 times per week with daily SPF. The risk increases substantially with higher-concentration products marketed online or imported from unregulated sources. Professional-grade TCA peels starting at 15–20% should only be applied by trained practitioners in clinical settings; consumer-grade products containing TCA at these concentrations risk chemical burns, scarring, and permanent pigmentation changes. FDA guidance notes that products above 10% AHA require a sun-sensitivity warning. If you purchase any exfoliant product online and the concentration exceeds 20% AHA or the pH is below 3.0, use only under dermatologist supervision or not at all.

No — sublingual immunotherapy (SLIT drops) does not treat allergic contact dermatitis from exfoliants, including enzyme exfoliant ACD. SLIT and allergy shots (SCIT) work by gradually desensitizing IgE-mediated immune responses to respiratory allergens (pollen, dust mites, pet dander). Enzyme exfoliant ACD is a Type IV T-cell-mediated hypersensitivity reaction, an entirely different immune pathway that is not addressed by IgE-targeted immunotherapy. The definitive treatment for enzyme ACD is lifelong avoidance of the sensitizing allergen. There is no immunotherapy currently available that reverses established Type IV contact sensitization to exfoliant proteins.